Vimarsana
Biggest News Aggregation in the World

Page 11 - Molbio Diagnostics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Molbio Diagnostics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Molbio Diagnostics Today - Breaking & Trending Today

cyient dlm ipo subscription: Cyient DLM IPO opens. Should you subscribe to the issue? - Vimarsana News

cyient dlm ipo subscription: Cyient DLM IPO opens. Should you subscribe to the issue?

Cyient DLM has initiated its initial public offering for subscription, with a price band of INR250-265 ($3.36-$3.55) and a proposed market capitalisation of INR2,102 crore. The entire IPO comprises fresh equity shares worth up to INR592 crore. Analysts recommend subscribing to the issue for the long term, given attractive valuations, strong growth potential and the company's focus on the entire life cycle of a product. Cyient DLM is a printed circuit board assembly solutions specialist with long-term relationships with customers such as Bharat Electronics and Thales Global Services.

Cyient DLM IPO opens tomorrow | 10 key things to know - Vimarsana News

Cyient DLM IPO opens tomorrow | 10 key things to know

Among its key risk factors is the fact that its top 10 clients constitute 91 percent of its revenues, and that forex fluctuations may adversely affect its profitability.

cyient dlm ipo: Cyient DLM IPO: What GMP indicates ahead of subscription tomorrow? - Vimarsana News

cyient dlm ipo: Cyient DLM IPO: What GMP indicates ahead of subscription tomorrow?

Cyient DLM is set to start its initial public offering on Tuesday, offering shares in the range of Rs 250-265 with a total value of up to Rs 592 crore. Ahead of the IPO, the company's shares have commanded a premium of Rs 90 in the unlisted markets. At the upper price band, Cyient DLM is available at P/E of 66.2x FY23 earnings. The firm specialises in the entire lifecycle of an electronics product, including design, build and maintenance, and is offering a fresh issue of equity shares.

Point of Care Molecular Diagnostics Market worth $3.4 billion - Vimarsana News

Point of Care Molecular Diagnostics Market worth $3.4 billion

/PRNewswire/ -- The point of care molecular diagnostics industry is poised for significant growth and advancements in the near future. With the increasing...

PE-backed Molbio's Natarajan on revenue growth and why it isn't chasing M&As - Vimarsana News

PE-backed Molbio's Natarajan on revenue growth and why it isn't chasing M&As

India’s diagnostics sector has always been a sweet spot for investors and gained further traction from private equity players during the Covid-19 pandemic. Temasek- and ......